Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
04:30pm, Wednesday, 13'th Nov 2024
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
11:57am, Tuesday, 12'th Nov 2024
Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue gro
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript
10:51pm, Monday, 04'th Nov 2024
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
09:00pm, Monday, 04'th Nov 2024
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall St
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
08:36pm, Monday, 04'th Nov 2024
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to loss of $0.29 per share a year ago.
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
04:10pm, Thursday, 31'st Oct 2024
Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was well-tolerated with few adverse events SPN-820 is a
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
04:25pm, Monday, 21'st Oct 2024
ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
04:05pm, Thursday, 17'th Oct 2024
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
05:12pm, Thursday, 10'th Oct 2024
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
04:30pm, Thursday, 19'th Sep 2024
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
11:25pm, Wednesday, 11'th Sep 2024
Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes ke
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
02:38pm, Wednesday, 11'th Sep 2024
Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
04:15pm, Wednesday, 28'th Aug 2024
ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
07:00am, Monday, 19'th Aug 2024
PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and comm
